title: Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
abstract: The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China.
authors.forename: Amber
authors.initials: A
authors.lastname: Farooqui
authors.affiliation: Infectious Diseases Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
authors.forename: Linxi
authors.initials: L
authors.lastname: Huang
authors.affiliation: Intensive Care Unit, Shantou Central Hospital, Shantou, China.
authors.forename: Suwu
authors.initials: S
authors.lastname: Wu
authors.affiliation: Department of Laboratory Medicine, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
authors.forename: Yingmu
authors.initials: Y
authors.lastname: Cai
authors.affiliation: Department of Pathology, Shantou University Medical College, Shantou, China.
authors.forename: Min
authors.initials: M
authors.lastname: Su
authors.affiliation: Infectious Diseases Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
authors.forename: Pengzhou
authors.initials: P
authors.lastname: Lin
authors.affiliation: Intensive Care Unit, Shantou Central Hospital, Shantou, China.
authors.forename: Weihong
authors.initials: W
authors.lastname: Chen
authors.affiliation: Intensive Care Unit, Shantou Central Hospital, Shantou, China.
authors.forename: Xibin
authors.initials: X
authors.lastname: Fang
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
authors.forename: Yisu
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China.
authors.forename: Tiansheng
authors.initials: T
authors.lastname: Zeng
authors.affiliation: Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Stephane G
authors.initials: SG
authors.lastname: Paquette
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China.
authors.forename: Adnan
authors.initials: A
authors.lastname: Khan
authors.affiliation: Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
authors.forename: Alyson A
authors.initials: AA
authors.lastname: Kelvin
authors.affiliation: Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada dkelvin@jidc.org.
authors.forename: David J
authors.initials: DJ
authors.lastname: Kelvin
mesh_terms: D000146:Acids, Carbocyclic; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D003517:Cyclopentanes / Q000494:pharmacology*; D004285:Dogs; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D064766:Influenza A Virus, H7N9 Subtype / Q000187:drug effects* / Q000201:enzymology / Q000254:growth & development; D007273:Injections, Intramuscular; D008168:Lung / Q000187:drug effects / Q000473:pathology / Q000821:virology; D061985:Madin Darby Canine Kidney Cells; D051379:Mice; D008810:Mice, Inbred C57BL; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000378:metabolism; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000821:virology; D053139:Oseltamivir / Q000494:pharmacology; D016019:Survival Analysis; D016896:Treatment Outcome; D019562:Viral Load / Q000187:drug effects; D014764:Viral Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D004791:Enzyme Inhibitors; D006146:Guanidines; D014764:Viral Proteins; D053139:Oseltamivir; D009439:Neuraminidase; C414210:peramivir